Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes

The integrase inhibitor (INI) dolutegravir (DTG; S/GSK1349572) has significant activity against HIV-1 isolates with raltegravir (RAL)- and elvitegravir (ELV)-associated resistance mutations. As an initial step in characterizing the different resistance profiles of DTG, RAL, and ELV, we determined th...

詳細記述

保存先:
書誌詳細
主要な著者: Hightower, Kendra E., Wang, Ruolan, DeAnda, Felix, Johns, Brian A., Weaver, Kurt, Shen, Yingnian, Tomberlin, Ginger H., Carter, H. Luke, Broderick, Timothy, Sigethy, Scott, Seki, Takahiro, Kobayashi, Masanori, Underwood, Mark R.
フォーマット: Artigo
言語:Inglês
出版事項: American Society for Microbiology 2011
主題:
Antiviral Agents
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3187001/
https://ncbi.nlm.nih.gov/pubmed/21807982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00157-11
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料